Praxis Precision Medicines Inc(PRAX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 5:28 PM ET (Korea 10/27 06:28)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -12.94 | Insider Own | 5.95% | Shs Outstand | 27.9M | Perf Week | 2.78% |
| Market Cap | 7.47B | Forward P/E | - | EPS next Y | 26.84% | Insider Trans | -0.69% | Shs Float | 26.3M | Perf Month | -4.77% |
| Enterprise Value | 6.71B | PEG | - | EPS next Q | -3.54 | Inst Own | 116.88% | Short Float | 15.95% | Perf Quarter | -9.61% |
| Income | -0.34B | P/S | - | EPS this Y | -1.74% | Inst Trans | 7.85% | Short Ratio | 9.14 | Perf Half Y | -19.22% |
| Sales | 0.00B | P/B | 5.57 | EPS next 5Y | - | ROA | -36.8% | Short Interest | 4.19M | Perf YTD | -9.28% |
| Book/sh | 48.04 | P/C | 9.84 | EPS past 3/5Y | 42.16% 13.34% | ROE | -38.86% | 52W High | -31.91% ($392.70) | Perf Year | 53.7% |
| Cash/sh | 27.17 | P/FCF | - | Sales past 3/5Y | - | ROIC | -25.29% | 52W Low | 73.12% ($154.45) | Perf 3Y | 1463.68% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -5.32% | Gross Margin | - | Volatility(W/M) | 4.79% 4.92% | Perf 5Y | -21.23% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 13.76 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 15.73 | EPS Q/Q | 13.23% | Profit Margin | - | RSI (14) | 46.4 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 15.73 | Sales Q/Q | - | SMA20 | 0.83% ($265.19) | Beta | 2.89 | Target Price | $650 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/6 | SMA50 | -13.37% ($308.66) | Rel Volume | 0.85 | Prev Close | $252.96 |
| Employees | 168 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 21.76% - | SMA200 | -15.09% ($314.91) | Avg Volume(3M) | 0.46M | Price | $267.39 |
| IPO | 2020/10/16 | Option/Short | Yes/Yes | Trades | 7755 | Volume | 389,827 | Change | 5.7% |
🧠 This clinical-stage biotech company develops therapeutics for central nervous system (CNS) disorders. Leveraging insights from hereditary epilepsy research, the company develops treatments for conditions related to neural excitation-inhibition imbalance, such as epilepsy and movement disorders. As a neuroscience healthcare stock, its share price is largely driven by the approval and clinical progress of its late-stage candidates.
Over the past 1 year, roughly in the middle
32% below its 1-year high.
Traded about as much as usual. That is 85% of its average volume.
PRAX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -1.7% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -21.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 116.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #37 of 594 in the industry
Based on market cap of $7B.
IBRX#34 ImmunityBio Inc $8B PER - 
ABVX#35 Abivax ADR $8B PER - 
AXSM#36 Axsome Therapeutics Inc $8B PER - PRAX#37 Praxis Precision Medicines Inc $7B PER - 
IONS#38 Ionis Pharmaceuticals Inc $7B PER - 
FAQ
What kind of company is PRAX?
PRAX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PRAX?
The market cap of PRAX is approximately $7.5B, ranking 1,077 within its sector.
What is the 52-week high and low for PRAX?
PRAX has recorded a 52-week high of $392.70 and a low of $154.45.
